DSP Nifty Healthcare Index Fund
- NAV as on 25 Sep 2026
- ₹11.77-0.47%1 day
- Return since launch
- 13.9%
- 52-week range
- ₹9.75 — ₹11.96
- AUM
- ₹25.41 Cr
DSP Nifty Healthcare Index Fund is a Sectoral-Pharma equity fund from DSP Mutual Fund with ₹25.41 Cr under management, launched in 2025. The expense ratio is 1.09% and the SEBI riskometer reading is Very High.
Performance
DSP Nifty Healthcare Index Fund NAV and returns
Growth of the fund against its category average over the period you pick.
Over 1Y this fund returned +17.3% against +19.5% for its category.
Performance
Returns
How the fund has done against its category and its benchmark.
| Period | Fund | vs category | Category | Benchmark |
|---|---|---|---|---|
| 1Y | 19.8% | −1.0 pts | 20.9% | 26.4% |
| Period | Fund | vs category | Category | Benchmark |
|---|---|---|---|---|
| 1M | 0.5% | +0.3 pts | 0.2% | -0.3% |
| 3M | 3.6% | −2.6 pts | 6.2% | 6.0% |
| 6M | 15.4% | −6.7 pts | 22.1% | 20.9% |
| 1Y | 17.3% | −3.5 pts | 20.9% | 19.5% |
Since launch (2 Jun 2025): 13.9%
Returns over one year are annualised. Shorter periods are absolute.
Costs & terms
Costs and terms
What the fund charges each year, and the rules around putting money in and taking it out.
Costs
1.08%
Expense ratio as on 25 Sep 2026
Charged yearly and already deducted from the NAV.
- Base expense
- 0.80%
- Brokerage
- 0.02%
- Transaction charges
- 0.00%
- Statutory levies
- 0.26%
- Exit load
- 0%
- Lock-in
- None
Terms
- Min SIP
- ₹3,000
- Min lumpsum
- ₹5,000
- Plan
- GROWTH
- Fund type
- OPEN-ENDED
- Benchmark
- NIFTY Healthcare TRI.
- Short-term capital gains
- Returns taxed at 20% if you redeem before 1 year
- Long-term capital gains
- After 1 year, returns above ₹1.25 lakh in a financial year are taxed at 12.5%
Risk
Risk
What the riskometer means for this fund, and how its ratios sit against the category.
Your principal is treated as being at very high risk — typically small cap, sectoral and thematic equity schemes.
Portfolio
DSP Nifty Healthcare Index Fund portfolio
Portfolio as of 31 Aug 2026
Asset allocation
- Equity100.0%
- Other0.0%
Market cap split
- Large49.5%
- Mid48.7%
- Small1.8%
- P/E
- 43.30
- P/B
- 5.63
Top holdings
| Holding | Sector | Weight | Value | 3M chg | 6M chg | 1Y chg |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | Healthcare | 18.08% | ₹4.59 Cr | +18.27% | +18.32% | +17.93% |
| Divi's Laboratories Ltd. | Healthcare | 10.35% | ₹2.63 Cr | +8.12% | +8.11% | +8.12% |
| Apollo Hospitals Enterprise Ltd. | Healthcare | 7.88% | ₹2.00 Cr | +8.07% | +8.02% | +8.02% |
| Cipla Ltd. | Healthcare | 6.82% | ₹1.73 Cr | +7.56% | +7.55% | +9.32% |
| Max Healthcare Institute Ltd. | Healthcare | 6.67% | ₹1.70 Cr | +6.89% | +8.09% | +8.95% |
| Laurus Labs Ltd. | Healthcare | 6.41% | ₹1.63 Cr | +5.08% | +4.16% | +3.50% |
| Torrent Pharmaceuticals Ltd. | Healthcare | 6.39% | ₹1.62 Cr | +4.42% | +4.51% | +3.88% |
| Dr. Reddy's Laboratories Ltd. | Healthcare | 6.05% | ₹1.54 Cr | +7.62% | +7.81% | +8.00% |
| Lupin Ltd. | Healthcare | 4.57% | ₹1.16 Cr | +5.27% | +5.56% | +4.78% |
| Aurobindo Pharma Ltd. | Healthcare | 4.09% | ₹1.04 Cr | +3.82% | +3.40% | +3.00% |
| Fortis Healthcare Ltd. | Healthcare | 4.07% | ₹1.03 Cr | +4.64% | +4.89% | +4.95% |
| Glenmark Pharmaceuticals Ltd. | Healthcare | 3.21% | ₹0.82 Cr | +3.28% | +3.20% | +3.02% |
| Alkem Laboratories Ltd. | Healthcare | 2.68% | ₹0.68 Cr | +3.08% | +3.28% | +2.98% |
| Biocon Ltd. | Healthcare | 2.53% | ₹0.64 Cr | +2.93% | +2.77% | +2.18% |
| Zydus Lifesciences Ltd. | Healthcare | 2.50% | ₹0.64 Cr | +2.59% | +2.30% | +2.55% |
| Ipca Laboratories Ltd. | Healthcare | 2.36% | ₹0.60 Cr | +2.03% | +2.12% | +2.01% |
| Mankind Pharma Ltd. | Healthcare | 2.36% | ₹0.60 Cr | +2.58% | +2.53% | +2.91% |
| Abbott India Ltd. | Healthcare | 1.15% | ₹0.29 Cr | +1.33% | +1.37% | +1.71% |
| Piramal Pharma Ltd. | Healthcare | 1.15% | ₹0.29 Cr | +1.03% | +0.96% | — |
| Syngene International Ltd. | Healthcare | 0.66% | ₹0.17 Cr | +0.80% | +0.80% | +1.24% |
| Others | Others | 0.02% | ₹0.01 Cr | +0.58% | -0.46% | -0.28% |
Sectors
Instruments
Recent changes
| Holding | From | To | Weight |
|---|---|---|---|
| Divi's Laboratories Ltd. | 8.89% | 10.35% | +1.46% |
| Lupin Ltd. | 5.09% | 4.57% | -0.52% |
| Max Healthcare Institute Ltd. | 7.10% | 6.67% | -0.43% |
| Cipla Ltd. | 7.20% | 6.82% | -0.38% |
| Aurobindo Pharma Ltd. | 3.80% | 4.09% | +0.29% |
| Glenmark Pharmaceuticals Ltd. | 2.92% | 3.21% | +0.29% |
| Laurus Labs Ltd. | 6.14% | 6.41% | +0.27% |
| Ipca Laboratories Ltd. | 2.11% | 2.36% | +0.25% |
| Others | -0.37% | -0.13% | +0.24% |
| Alkem Laboratories Ltd. | 2.92% | 2.68% | -0.24% |
| Sun Pharmaceutical Industries Ltd. | 18.30% | 18.08% | -0.22% |
| Fortis Healthcare Ltd. | 4.28% | 4.07% | -0.21% |
| Apollo Hospitals Enterprise Ltd. | 8.01% | 7.88% | -0.13% |
| Torrent Pharmaceuticals Ltd. | 6.52% | 6.39% | -0.13% |
| Biocon Ltd. | 2.64% | 2.53% | -0.11% |
| Abbott India Ltd. | 1.26% | 1.15% | -0.11% |
| Piramal Pharma Ltd. | 1.06% | 1.15% | +0.09% |
| Mankind Pharma Ltd. | 2.43% | 2.36% | -0.07% |
| Zydus Lifesciences Ltd. | 2.45% | 2.50% | +0.05% |
| Dr. Reddy's Laboratories Ltd. | 6.08% | 6.05% | -0.03% |
| Syngene International Ltd. | 0.64% | 0.66% | +0.02% |
Compare
Similar funds
The rest of the category, so this fund’s numbers have something to sit against.
| Fund | AUM | Expense | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|
| Category average | ₹3,579 Cr | 2.19% | 27.3% | 17.7% | 20.1% |
 ICICI Prudential Healthcare Fund | ₹6,996 Cr | 2.07% | 14.5% | 14.2% | 19.4% |
 SBI Healthcare Opportunities Fund | ₹5,796 Cr | 1.99% | 33.1% | 19.9% | 22.2% |
 Mirae Asset Healthcare Fund | ₹3,555 Cr | 2.03% | 29.9% | 18.4% | 19.7% |
 UTI Healthcare Fund | ₹1,444 Cr | 2.21% | 30.4% | 19.1% | 21.1% |
 LIC MF Healthcare Fund | ₹103 Cr | 2.67% | 28.7% | 16.9% | 17.9% |
About
About this fund
The scheme’s own words, its benchmark and the people running it.
Investment objective
The scheme seeks to generate returns that are commensurate with the performance of the Nifty Healthcare Index, subject to tracking error.
Fund managers
- Anil GhelaniMr. Ghelani has done B. Com., CFA & CAPrior to joining DSP Mutual Fund he has worked with IL&FS, S. R. Batliboi, V. C. Shah & Co.
- Diipesh ShahMr. Shah is a B Com, ACA, Candidate of the CFA Program, CFA Institute USA, Level I ClearedPrior to joining DSP Mutual Fund, he has worked with JM Financial, Centrum Broking, IDFC Securities, ICICI Securities and IIFL Capital Pte Ltd Singapore.
Tools
Return calculator
What ₹10,000 a month in this fund would have grown to over each period, based on its past returns.
| Over the past | Total investment | Would’ve become | Growth | Returns |
|---|---|---|---|---|
| 6 months15.42% absolute | ₹60,000 | ₹69,252 | 15.42% | |
| 1 year17.32% annualised | ₹1,20,000 | ₹1,31,876 | 9.90% |
Returns for 1 year and longer are annualised (CAGR); 6-month figures are absolute. Past returns are not a forecast.
How this is calculated
Each monthly instalment grows at the fund’s annualised return ÷ 12 per month until the end of the period, the same formula as our SIP calculator.
The amount compounds once a year at the fund’s CAGR for that period, the same formula as our lumpsum calculator.
Questions
Frequently asked questions
The things people ask about this scheme.